Kaitlyn D’Onofrio

DocwireNews

<p>A recent cohort study compared fracture outcomes in patients with osteoporosis being treated with denosumab (PROLIA from Amgen) versus alendronate and found both treatments carried the same risk for hip fracture and overall fracture.<p>&ldquo;Head-to-head randomized clinical trials showed greater efficacy of denosumab vs alendronate in improving bone mineral density,&rdquo; the study authors wrote. &ldquo;Although there is an association of changes in bone mineral density with reductions in fracture risk, the magnitude of the association is not well established.&rdquo;</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">New paper with the mighty <a href="https://twitter.com/DCEAarhus?ref_src=twsrc%5Etfw">@dceaarhus</a> cols <a href="https://twitter.com/AlmaBPedersen?ref_src=twsrc%5Etfw">@AlmaBPedersen</a> <a href="https://twitter.com/ToftSorensen?ref_src=twsrc%5Etfw">@ToftSorensen</a> <a href="https://twitter.com/EhrensteinVera?ref_src=twsrc%5Etfw">@EhrensteinVera</a> <br>&ldquo;Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate&rdquo;<a href="https://t.co/U4XKimyHOy">https://t.co/U4XKimyHOy</a><a href="https://twitter.com/CSMOxford?ref_src=twsrc%5Etfw">@CSMOxford</a> <a href="https://twitter.com/ndorms?ref_src=twsrc%5Etfw">@ndorms</a></p>
<p>&mdash; dani prieto-alhambra (@prieto_alhambra) <a href="https://twitter.com/prieto_alhambra/status/1119331452456452102?ref_src=twsrc%5Etfw">April 19, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>To conduct their trial, the researchers collected Danish health registry data on patients aged &ge; 50 years initiating either denosumab or alendronate between May 2010 and December 2017. Patients were excluded if they had a recorded dispensing of any osteoporosis medication during the one-year period before the index date or if they had a history of cancer or Paget disease in the 10 years before the index date, because they are both &ldquo;alternative indications for denosumab and alendronate,&rdquo; the study authors noted. The primary outcome was hospitalization for hip fracture, and the secondary outcome was hospitalization for any fracture.</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">It&rsquo;s important to know the mechanism of action of each treatment. After denosumab therapy we should initiate another antiosteoporotic treatment (preferably bisphosphonates) as denosumab is a monoclonal antibody and has no skeletal retention <a href="https://twitter.com/hashtag/FakeNews?src=hash&amp;ref_src=twsrc%5Etfw">#FakeNews</a>  <a href="https://t.co/Mr1v8g8e9Y">https://t.co/Mr1v8g8e9Y</a></p>
<p>&mdash; Laia Gifre (@laiagifre1) <a href="https://twitter.com/laiagifre1/status/1115621474533019650?ref_src=twsrc%5Etfw">April 9, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><h2><strong>Similar Patient Populations and Outcomes</strong></h2><p>The analysis included 92,355 patients (mean age, 71 years; 81.3% female): 4,624 initiating denosumab and 87,731 initiating alendronate. There were more men in the alendronate group than the denosumab cohort (19% vs. 12.7%). Age breakdown was similar between the groups: in both the denosumab and alendronate cohorts, most patients were aged between 70 and 79 years (32.4% vs. 32.3%, respectively), followed by 60&ndash;69 years (29.9% vs. 30.7%, respectively). After three years of follow-up, cumulative hip fracture incidence was 3.7% in the denosumab group and 3.1% in the alendronate cohort. In both groups, the cumulative incidence for any fracture was 9.0%.</p><p>The overall adjusted hazard ratios (aHRs) for denosumab compared to alendronate were 1.08 (95% CI, 0.92-1.28) for hip fracture and 0.92 (95% CI, 0.83-1.02) for any fracture. The researchers also evaluated aHRs for hip fracture based on previous fracture history: comparing denosumab to alendronate, the aHR for hip fracture among patients with history of any fracture was 1.07 (95% CI, 0.85-1.34), and for patients with no fracture history, it was 1.05 (95% CI, 0.83-1.32); when evaluating for any fracture comparing denosumab to alendronate, aHRs were 0.84 (95% CI, 0.71-0.98) for those with previous fracture and 0.77 (95% CI, 0.64-0.93) for those without previous fracture.</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Global Alendronate Market Insights, Pharmaceuticals, Experiments, Research, Analysis, Evolutions and Forecast to 2025 &ndash; <a href="https://t.co/EsTzUlhsPa">https://t.co/EsTzUlhsPa</a> <a href="https://t.co/qeYzCtGW74">pic.twitter.com/qeYzCtGW74</a></p>
<p>&mdash; EPR Network (@eprnetwork) <a href="https://twitter.com/eprnetwork/status/1118805234158116864?ref_src=twsrc%5Etfw">April 18, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>&ldquo;The results did not materially change after excluding patients with a recent fracture at the same site as a given outcome or after excluding atypical femoral fractures from the hip fracture outcome definition,&rdquo; the study authors further observed. &ldquo;Extending the required therapy-free period to 5 years to define new use yielded an aHR for hip fracture of 1.07 (95% CI, 0.88-1.30) and for any fracture of 0.93 (95% CI, 0.82-1.05) for denosumab compared with alendronate.&rdquo;</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Cohort study from Danish registries shows similar risks of hip/any fracture in initiators of <a href="https://twitter.com/hashtag/denosumab?src=hash&amp;ref_src=twsrc%5Etfw">#denosumab</a> and <a href="https://twitter.com/hashtag/alendronate?src=hash&amp;ref_src=twsrc%5Etfw">#alendronate</a> in routine clinical practice <a href="https://t.co/2AYcPDRl40">https://t.co/2AYcPDRl40</a> <a href="https://twitter.com/AlmaBPedersen?ref_src=twsrc%5Etfw">@AlmaBPedersen</a> <a href="https://twitter.com/DCEAarhus?ref_src=twsrc%5Etfw">@dceaarhus</a> <a href="https://t.co/xjAzxcPBeR">pic.twitter.com/xjAzxcPBeR</a></p>
<p>&mdash; JAMA Network Open (@JAMANetworkOpen) <a href="https://twitter.com/JAMANetworkOpen/status/1120281093436051458?ref_src=twsrc%5Etfw">April 22, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>One of the study&rsquo;s limitations was potential residual confounding: &ldquo;For example, renal impairment was more prevalent in the denosumab cohort than in the alendronate cohort but is incompletely measured by hospital diagnoses,&rdquo; the researchers wrote. Data were also lacking on frailty, socioeconomic status, lifestyle, and bone mineral density. Finally, the researchers could not stratify patients into more than two age groups.</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Generic zometa is probably just as safe and effective. $8 per year &ndash; one dose does it  less than the copay on Alendronate. And likely costs less than branded Denosumab</p>
<p>&mdash; Kevin Knopf (@drkevinknopf) <a href="https://twitter.com/drkevinknopf/status/1118302010858565633?ref_src=twsrc%5Etfw">April 16, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p></p>


Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

No Difference in Fracture Risk in Patients Taking Denosumab Versus Alendronate

Osteoporosis

A recent cohort study compared fracture outcomes in patients with osteoporosis being treated with denosumab versus alendronate and found both treatments carried the same risk ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe